Trial Profile
A phase III, 12-week, multicentre, double-blind, randomised, placebo- and active comparator-controlled, parallel group study to investigate the efficacy and safety of GW406381, 5mg, 10mg, 25mg, and 50mg administered orally once daily, in adults with rheumatoid arthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs GW 406381 (Primary) ; Celecoxib
- Indications Musculoskeletal pain; Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors GSK
- 13 Oct 2012 Planned number of patients changed from 2208 to 2210.
- 20 May 2009 Additional locations identified as reported by ClinicalTrials.gov.
- 28 Jun 2007 Status changed from recruiting to completed